Studies in cervical cancer have shown that BRD4 inhibitors can enhance the response of tumor cells to chemotherapy by inhibiting the expression of HPV16 E6, and are thus expected to be potential new targets for cervical cancer therapy (Rataj et al., 2019). Here, BRD4 is linked to cervical carcinoma.